Biotechnology, Pharmaceuticals, and Research by Summit Therapeutics

10.36
0.2150
2.03 %
Daily range
Weekly range
  • Sergey Shendetskyi
  • 56 min ago
Summit Therapeutics stock drops about 5.5% after FDA issues Complete Response Letter on ivonescimab
Summit Therapeutics (SMMT) fell 5.49% after investors reacted to the recent regulatory setback in its lung cancer drug application. The move is supported by strong seller pressure, with the stock ...
  • Parshwa Turakhiya
  • 16.11.2026
SMMT slides nearly 15% as technical weakness follows FDA rejection on BLA
Summit Therapeutics Inc. (SMMT) dropped 14.68% today after the FDA issued a Complete Response Letter on its ivonescimab BLA, which delayed a key regulatory milestone for the company. The severity ...
  • Hlib Chabaniuk
  • 16.11.2026
Summit Therapeutics stock falls 6.1% after Ivonescimab application update
Summit Therapeutics issued an update on its Ivonescimab Biologics License Application. The stock is down 6.1% on the day at $14.15.Summit Therapeutics provided an update on the regulatory status ...
  • Mykhailo Ihnatenko
  • 11.11.2026
Why is Summit Therapeutics stock down 4.7% today?
Summit Therapeutics Inc. (SMMT) fell 4.77% today, pressured by intraday volatility and mixed momentum signals. This downside move contradicts the prevailing bullish trend structure, with prices ...
  • Viktoras Karapetjanc
  • 06.11.2026
Summit Therapeutics stock falls 12.3% after financial results
Summit Therapeutics reported financial results and operational progress for the third quarter and nine months ended September 30, 2026. The stock is down 12.3% on the day at $14.19.Summit ...
  • Jainam Mehta
  • 27.10.2026
SMMT climbs over 3% after technical oversold signals spark short-term buying
Summit Therapeutics (SMMT) advanced 3.21% as technical pressure eased following oversold signals and a volatile open that attracted short-term buyers. The rebound looks limited, with SMMT still ...
  • Andrey Mastykin
  • 22.10.2026
Summit Therapeutics enters clinical trial collaboration after stock ends session down 1.6%
Summit Therapeutics announced a new clinical trial partnership with the ECOG-ACRIN Cancer Research Group to study ivonescimab in first-line biliary tract cancer. Shares are down 1.6% on the day at ...
  • Anastasiia Chabaniuk
  • 19.10.2026
Summit Therapeutics stock rises nearly 6% as pivotal Phase II trial for ivonescimab begins in renal cell carcinoma
Summit Therapeutics (SMMT) jumped 5.68% after announcing the opening of clinical trial sites for a pivotal Phase II study of ivonescimab in advanced clear cell renal cell carcinoma. The rebound ...
  • Ashutosh Sureka
  • 13.10.2026
Why is Summit Therapeutics stock down 8.2% today?
Summit Therapeutics (SMMT) slumped 8.23% as seller momentum persisted, even as anticipation builds for its upcoming Q3 2026 earnings release and a newly announced joint oncology initiative with ...
  • Anastasiia Chabaniuk
  • 05.10.2026
Why is Summit Therapeutics stock up 4.1% today?
Summit Therapeutics (SMMT) climbed 4.12% after the company confirmed receipt of a $2 billion equity investment from AstraZeneca to accelerate cancer drug development, marking a significant cash ...
  • Aleksandra Chaikina
  • 30.09.2026
SMMT climbs nearly 5% after AstraZeneca funds cancer drug development
Summit Therapeutics (SMMT) surged 4.7% after announcing a $2 billion equity investment from AstraZeneca to fund the development of its cancer therapy pipeline. The move is further supported by the ...
  • Anton Kharitonov
  • 23.09.2026
Summit Therapeutics falls around 4.5% as weak profitability and low growth drive investor caution
Summit Therapeutics (SMMT) slid 4.59% as weak profitability and low growth fundamentals reported by HC Wainwright & Co. accentuated investor hesitancy. The decline is currently limited by the ...
  • Ivan Andriyenko
  • 21.09.2026
Summit Therapeutics stock falls over 5% as HARMONi trial update sparks selling pressure
Summit Therapeutics (SMMT) dropped 5.13% after updated Phase III HARMONi clinical trial data for ivonescimab showed consistent overall survival and safety outcomes in both Asian and Western ...
  • Mira Kyivska
  • 15.09.2026
Summit Therapeutics shares drop about 4.5% after volatility follows bullish clinical data
Summit Therapeutics (SMMT) slid 4.56% as selling pressure followed an extended overbought rally, even as clinical trial data for its lung cancer candidate provided a strong fundamental backdrop. ...
  • Mira Kyivska
  • 14.09.2026
Summit Therapeutics stock rises over 5% as new ivonescimab trial data boosts outlook
Summit Therapeutics (SMMT) surged 5.34% after highlighting new overall survival data from Akeso’s clinical trials involving ivonescimab, fueling investor optimism over its clinical progress. The ...
  • Sergey Shendetskyi
  • 11.09.2026
Summit Therapeutics stock rises nearly 4% as technical momentum and strong trend signals fuel buying
Summit Therapeutics (SMMT) advanced 3.95% today on the back of continued technical buying, as strong trend momentum and bullish signals drive the move. The rally is supported by SMMT trading above ...
  • Ashutosh Sureka
  • 10.09.2026
What's behind Summit Therapeutics' latest stock pullback?
Summit Therapeutics (SMMT) fell 3.14% amid strong overbought signals and intraday selling pressure in the absence of new corporate catalysts. The move is contradicted by the stock’s position ...
  • Sergey Shendetskyi
  • 03.09.2026
What's behind Summit Therapeutics's latest 15.1% stock surge?
Summit Therapeutics (SMMT) surged 15.14% after positive clinical trial results and a favorable regulatory outlook for its lead asset ivonescimab drove strong demand. The move is supported by a ...
  • Jainam Mehta
  • 28.08.2026
SMMT slides around 3.5% as technical weakness persists without new corporate news
Summit Therapeutics (SMMT) declined 3.56% today as technical factors led sentiment in the absence of any fresh corporate catalysts. The move is supported by the stock remaining below key moving ...
  • Ciaran Ryan
  • 25.08.2026
What's behind Summit Therapeutics's latest 4.7% stock surge?
Summit Therapeutics (SMMT) advanced 4.69% after an upside gap, with the move linked to short covering and a technical bounce. The rebound looks limited, as the stock continues to trade below all ...
  • Andreas Kristo
  • 24.08.2026
SMMT slides around 6.5% as stock remains below key moving averages with weak momentum
Summit Therapeutics (SMMT) slid 6.46% under sharp selling pressure, as technical momentum signaled a continuation of its recent decline in the absence of a fresh catalyst. The downtrend is ...